Department of Microbiology, Medical School, University of Thessaly, Larissa 41110, Greece.
Department of Microbiology, Medical School, University of Athens, Athens 11527, Greece.
Antibiotics (Basel). 2013 Mar 11;2(1):73-82. doi: 10.3390/antibiotics2010073.
Acinetobacter baumannii may exhibit phenotypic heterogeneous growth under exposure to antibiotics. We investigated the in vitro characteristics of A. baumannii isolates grown heterogeneously in the presence of meropenem and their virulence evaluated in experimental infections treated with meropenem. Five clinical A. baumannii isolates and the respective heterogeneously grown subpopulations were tested by agar dilution minimum inhibitory concentration (MIC) testing, pulsed field gel electrophoresis (PFGE), population analysis using meropenem and growth curves. The virulence of isolates and the therapeutic efficacy of three meropenem dosing schemes was evaluated in a neutropenic murine thigh infection model. The clinical isolates were meropenem-susceptible (MICs 1 to 4 mg/liter) and exhibited three distinct PFGE patterns. In all clinical isolates, population analysis yielded heterogeneously grown colonies. After seven subcultures in antibiotic-free media, resistant MIC levels were retained in two isolates (heteroresistant), while three isolates were reversed to susceptible MICs (persisters). Clinical isolates and heterogeneous subpopulations had similar growth rates. The heterogeneously grown A. baumannii subpopulations had reduced virulence, killing considerably fewer animals than the respective clinical isolates without treatment. The meropenem treatment outcome was similar in infections caused by the clinical and the heterogeneous isolates, irrespective to their MICs. In vitro meropenem exposure induces phenotypic heterogeneous growth in A. baumannii. Compared with the parental clinical isolates, the heterogeneously grown subpopulations exhibited lower virulence, killing fewer mice and responding equally to meropenem treatment, despite their higher MICs.
鲍曼不动杆菌在接触抗生素时可能表现出表型异质生长。我们研究了在美罗培南存在下异质生长的鲍曼不动杆菌分离株的体外特征,并评估了用美罗培南治疗的实验感染的毒力。通过琼脂稀释最低抑菌浓度(MIC)测试、脉冲场凝胶电泳(PFGE)、用美罗培南进行群体分析和生长曲线对 5 株临床鲍曼不动杆菌分离株及其相应的异质生长亚群进行了测试。在中性粒细胞减少症小鼠大腿感染模型中评估了分离株的毒力和三种美罗培南给药方案的治疗效果。临床分离株对美罗培南敏感(MIC 为 1 至 4 毫克/升),并表现出三种不同的 PFGE 模式。在所有临床分离株中,群体分析均产生异质生长的菌落。在无抗生素的培养基中进行了七次传代后,两株分离株保留了耐药 MIC 水平(异质耐药),而三株分离株则恢复为敏感 MIC(持续存在)。临床分离株和异质亚群具有相似的生长速度。异质生长的鲍曼不动杆菌亚群的毒力降低,未经治疗时比相应的临床分离株杀死的动物明显减少。感染由临床和异质分离株引起时,美罗培南治疗效果相似,与它们的 MIC 无关。体外美罗培南暴露会诱导鲍曼不动杆菌表型异质生长。与亲本临床分离株相比,异质生长的亚群表现出较低的毒力,杀死的小鼠更少,并且对美罗培南治疗的反应相同,尽管它们的 MIC 更高。